Daclizumab
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsing-Remitting Multiple Sclerosis (RRMS)
Conditions
Relapsing-Remitting Multiple Sclerosis (RRMS)
Trial Timeline
Apr 18, 2017 → Sep 12, 2018
NCT ID
NCT02881567About Daclizumab
Daclizumab is a phase 3 stage product being developed by AbbVie for Relapsing-Remitting Multiple Sclerosis (RRMS). The current trial status is terminated. This product is registered under clinical trial identifier NCT02881567. Target conditions include Relapsing-Remitting Multiple Sclerosis (RRMS).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02881567 | Phase 3 | Terminated |
Competing Products
20 competing products in Relapsing-Remitting Multiple Sclerosis (RRMS)